DianaACarlinoFFranzeseE, et al.Early triple negative breast cancer: conventional treatment and emerging therapeutic landscapes. Cancers (Basel)2020; 12: 819.
2.
LiJYuKPangD, et al.Adjuvant capecitabine With docetaxel and cyclophosphamide Plus epirubicin for triple-negative breast cancer (CBCSG010): an open-label, randomized, multicenter, phase III trial. J Clin Oncol 2020 Jun 1;38(16):1774–1784. DOI: 10.1200/JCO.19.02474
3.
LluchABarriosCHTorrecillasL, et al.Phase III trial of adjuvant capecitabine after standard Neo-/adjuvant chemotherapy in patients With early triple-negative breast cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol2020; 38: 203–213.
4.
MasudaNLeeSJOhtaniS, et al.Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med2017; 376: 2147–2159.
5.
O’ShaughnessyJKoeppenHXiaoY, et al.Patients with slowly proliferative early breast cancer have Low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clin Cancer Res2015; 21: 4305–4311.
6.
JoensuuHKellokumpu-LehtinenPLHuovinenR, et al.Adjuvant capecitabine in combination With docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncol2017; 3: 793–800.
7.
O’ShaughnessyJMilesDVukeljaS, et al.Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol2002; 20: 2812–2823.
